Oct 29, 2010 by Brian Orelli, PhDGet Rich! Partner Your DrugWhy biotechs go up when they license their drugs.
Oct 29, 2010 by Brian Orelli, PhDNot Exact, but Close EnoughA new test to detect colorectal cancer looks promising.
Oct 29, 2010 by Brian Orelli, PhDThe Sanofi-Genzyme Drama Has Nothing on These Potential BuyoutsM&A, biotech style.
Oct 29, 2010 by Brian Orelli, PhDFatter Wallet? Maybe Some Other Day.VIVUS' Qnexa gets turned down by the FDA
Oct 29, 2010 by Brian Orelli, PhDFDA Gives Treats to a Few DrugmakersLooks like the agency still knows how to use that approval stamp.
Oct 29, 2010 by Brian Orelli, PhDThis Drugmaker Needs a Growth PrescriptionMerck is in wait and drop mode.
Oct 28, 2010 by Brian Orelli, PhDThe 3 Words Every Biotech Investor Wants to HearBetter than "FDA approved drug."
Oct 28, 2010 by Brian Orelli, PhDThis Takeover's Going Nowhere FastThe Sanofi-Genzyme Drama, Take 37.
Oct 27, 2010 by Brian Orelli, PhDBiogen Idec's Fight-Back PlanNovartis' Gilenya is coming, but Biogen has a backup plan.
Oct 26, 2010 by Brian Orelli, PhDThank Goodness for Amgen's New KidsThe old drugs are dragging down growth.
Oct 26, 2010 by Brian Orelli, PhDWhere's the Growth in Big Pharma?The prevailing trend isn't a good one.
Oct 21, 2010 by Brian Orelli, PhDAbbott Just Can't Get Any LoveEarnings beat, but revenues disappoint.
Oct 21, 2010 by Brian Orelli, PhDGenzyme: Nice Quarter, Still Too ExpensiveBuyout offers will do that.
